Skimmianine Attenuates Osteoclast Activity by Suppressing ERp57‐ Driven Calcium Oscillations/Calcineurin/Nfatc1 Signalling in Postmenopausal Osteoporosis
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Yongshuang Lv und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Joint Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: NFATC Transcription Factors, Calcineurin, Osteoclasts, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taishan Scholar Foundation of Shandong Province, Shandong Provincial Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Postmenopausal osteoporosis is primarily attributed to the hyperactivation of osteoclast‐induced bone resorption. The differentiation and function of osteoclasts rely on the regulation of calcium oscillations/calcineurin/nuclear factor of activated T cells (Nfat) pathway. Therefore, the development of natural compounds that aim at the crucial regulator of the aforementioned pathway is essential for the suppression of osteoclastogenesis and its clinical application. Skimmianine (Ski), a furoquinoline alkaloid extracted from the Zanthoxylum genus, is known for its anti‐inflammatory properties. Yet, its exact role in osteoclast differentiation and function remains largely undefined. Herein, we evaluate the impact of Ski on osteoclastogenesis and elucidate the molecular mechanism involved. We conducted network pharmacology and molecule structure‐based pharmacokinetics analyses on Ski, followed by experimental validations on osteoclastogenesis in vitro and ovariectomy (OVX) mice model in vivo. The network pharmacology results indicated Ski's therapeutic effects predominantly influence the calcium signalling pathway by controlling cytosolic calcium concentration in response to bone resorption during osteoporosis. Pharmacokinetic analyses revealed Ski's excellent oral bioavailability. Furthermore, experimental validations revealed that Ski inhibited the formation of multinucleated osteoclasts in a concentration‐dependent manner without affecting cell viability, while impeding osteoclast‐related gene expression. The underlying mechanism involved the Ski‐induced downregulation of calcineurin/Nfatc1 expression through modulation of ERp57‐driven calcium oscillations. Micro‐CT results confirmed that Ski treatment substantially curbed the progression of osteoporosis by mitigating bone loss. In conclusion, our findings indicated that Ski suppressed osteoclast formation by suppressing ERp57‐driven calcium oscillations/calcineurin/Nfatc1 signalling, thus establishing Ski as a promising therapeutic alternative for osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Joint Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
- Orthopaedic Research Laboratory, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- Wenzhou Hospital of Traditional Chinese Medicine Affiliated Zhejiang University of Traditional Chinese Medicine, Wenzhou, China.
- Department of Joint Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
- The Second Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Förderung
- Taishan Scholar Foundation of Shandong Province
- Shandong Provincial Natural Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Lv, Y., Zhang, X., Lu, Q., Zhou, Y., Wang, W., Yang, M., Yuan, T., Liu, Y., Sun, S., & Li, Z. (2025). Skimmianine Attenuates Osteoclast Activity by Suppressing ERp57‐ Driven Calcium Oscillations/Calcineurin/Nfatc1 Signalling in Postmenopausal Osteoporosis. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70777
Vancouver
Lv Y, Zhang X, Lu Q, Zhou Y, Wang W, Yang M, et al. Skimmianine Attenuates Osteoclast Activity by Suppressing ERp57‐ Driven Calcium Oscillations/Calcineurin/Nfatc1 Signalling in Postmenopausal Osteoporosis. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70777
BibTeX
@article{Lv2025,
author = {Lv, Yongshuang and Zhang, Xin and Lu, Qizhen and Zhou, Yi and Wang, Weiyi and Yang, Maosheng and Yuan, Tao and Liu, Yikai and Sun, Shui and Li, Ziqing},
title = {Skimmianine Attenuates Osteoclast Activity by Suppressing ERp57‐ Driven Calcium Oscillations/Calcineurin/Nfatc1 Signalling in Postmenopausal Osteoporosis},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70777}
}
EUVIMED